GrantForecasted — not yet open✓ Small businesses may apply
Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)
Food and Drug Administration
Award ceiling
$350,000
Award floor
$350,000
- Opportunity #
- FOR-FD-24-008
- Agency
- Food and Drug Administration
- ALN (CFDA)
- 93.103
- Status
- forecasted
- Posted
- Nov 24, 2023
- Funding instrument
- Cooperative Agreement
- Category
- Agriculture, Consumer Protection, Food and Nutrition
- Cost sharing required
- No
Who can apply
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •For profit organizations other than small businesses
- •Special district governments
- •Public and State controlled institutions of higher education
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Native American tribal organizations (other than Federally recognized tribal governments)
- •Public housing authorities/Indian housing authorities
- •Independent school districts
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Native American tribal governments (Federally recognized)
- •Small businesses
- •Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
- •Private institutions of higher education
- •State governments
- •County governments
- •City or township governments
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.The FDA will not accept duplicate or highly overlapping applications under review at the same time. This means that the FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statementfrom the review of the previous new (A0) application.
Contact
Terrin Brown Grantor · terrin.brown@fda.hhs.gov